Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Neuroactive steroids, compositions, and uses thereof

a technology applied in the field of neuroactive steroids and compositions, to achieve the effect of reducing depression

Inactive Publication Date: 2017-12-07
SAGE THERAPEUTICS
View PDF1 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a method for reducing tremor in humans by using a specific compound. The method can reduce the amplitude of tremor by at least 5%, 10%, 20%, 30%, 40%, or 50% compared to before the method is provided. This reduction in tremor can provide therapeutic benefits in treating diseases or disorders with symptoms associated with tremor. The method can improve overall therapy, reduce symptoms or causes of disease, or enhance the effectiveness of another therapeutic agent. The term "therapeutically effective amount" refers to the amount of compound needed to provide therapeutic benefits in treating a disease or disorder.

Problems solved by technology

In some embodiments, the method results in sedation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Neuroactive steroids, compositions, and uses thereof
  • Neuroactive steroids, compositions, and uses thereof
  • Neuroactive steroids, compositions, and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Human Phase 1 Study of Allopregnanolone

[0358]A Double-Blind, Placebo-Controlled, Two-Period Crossover, Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, Efficacy of Allopregnanolone Injection in the Treatment of Patients with Essential Tremor

Study Design

[0359]A double-blind, proof-of-concept study designed to evaluate the safety, tolerability, PK, and efficacy of allopregnanolone injection in male or female patients with essential tremor in the upper limb. Each patient's involvement is up to 72 days, including up to a 28-day Screening Period, 12-hour Treatment Period 1 with 12-hour follow-up, 7-day (+ / −3 days) Washout Period, 12-hour Treatment Period 2 with 12-hour follow-up, a 7-day Follow-up Visit (Day 18 + / −1 day) plus an additional 23 days of SAE follow-up (with an End-of-Study visit via call on day 41). A representation of the Trial Design and activities is shown on FIG. 1.

[0360]Screening Period: As depicted in FIG. 1, the Screening Period begins beg...

example 2

Human Phase 1 Study of Allopregnanolone

[0418]An Open-Label Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Allopregnanolone Injection in the Treatment of Adult Female Patients with Postpartum Depression

Study Design

[0419]A double-blind, placebo-controlled study designed to evaluate the safety, tolerability, PK, and efficacy of allopregnanolone injection in adult female patients diagnosed (by Structured Clinical Interview for DSM-V Axis I Disorders [SCID-I]) with severe PPD. Each patient's involvement is up to 37 days, including up to a 3-day screening period, 4-day (84-hour) active treatment period, and a 7-day AE follow-up period plus an additional 23 days of SAE follow-up (with a telephone call at day 11 and day 34).

[0420]Screening Period: The Screening Period begins with the signature of the informed consent form (ICF) in the Perinatal Psychiatry Inpatient Unit (PPIU) at the Screening Visit, which can occur on any one calendar day of t...

example 3

A Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Allopregnanolone Injection in the Treatment of Depression

Primary Objective:

[0484]To compare the effects of Allopregnanolone Injection and placebo infused intravenously for 48 hours on subject symptom response as measured by the Hamilton Rating Scale for Depression, 17-item (HAM-D-17)

Secondary Objectives:

[0485]To compare the effects of Allopregnanolone Injection and placebo on:[0486]Clinician evaluation as measured by the Clinical Global Impression-Improvement Scale (CGI-I)[0487]Sedation using the Stanford Sleepiness Scale (SSS)[0488]Safety and tolerability, assessed using adverse event reporting, vital sign measurement, laboratory data, ECG parameters, and suicidal ideation using the Columbia-Suicide Severity Rating Scale (C-SSRS)[0489]Depressive symptom severity, reproductive mood disorders, and sleepiness as measured by the following clinician- and subject-rated outcome measures: Edin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

Described herein are methods of treating tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).

Description

CLAIMS OF PRIORITY[0001]This application claims priority to U.S.S.N. 62 / 047,599, filed Sep. 8, 2014; U.S.S.N. 62 / 170,596, filed Jun. 3, 2015; and U.S.S.N. 62 / 213,015, filed Sep. 1, 2015, the entire contents of which are incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]Brain excitability is defined as the level of arousal of an animal, a continuum that ranges from coma to convulsions, and is regulated by various neurotransmitters. In general, neurotransmitters are responsible for regulating the conductance of ions across neuronal membranes. At rest, the neuronal membrane possesses a potential (or membrane voltage) of approximately −70 mV, the cell interior being negative with respect to the cell exterior. The potential (voltage) is the result of ion (K+, Na+, Cl+, organic anions) balance across the neuronal semipermeable membrane. Neurotransmitters are stored in presynaptic vesicles and are released under the influence of neuronal action potentials. When released int...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/573A61K9/00A61K47/40
CPCA61K31/573A61K9/0053A61K47/40A61K9/0019A61K31/57A61P25/14A61P25/24A61P25/28A61K31/56
Inventor KANES, STEPHEN JAYCOLQUHOUN, HELEN
Owner SAGE THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com